The commonly used immunosupprcssivc regimen after solid organ transplantation consists of eyclosporine A, azathioprinc and steroids. Azathioprine, which is known to carry the risk of severe myelosuppression, is catabolized in vivo by xanthine oxidase and thiopurinc methyltransferase, an enzyme which exhibils a common genetic polymorphism; 11% of Caucasians are heterozygous and 0.3% are homozygous wilh respect to thiopurinc methyltransferase deficiency. Toxicity and immunosuppressive effects have been attributed to the 6-thioguaninc nucleotides generated from azathioprinc. We have studied thiopurine methyltransferase activity and 6-thioguaninc nucleoiide concentrations in erylhrocytcs from 39 heart and kidney recipients. Brythrocylc thiopurine methyltransferase was determined by a radioen/ymatic assay and erylhrocyte 6-thiogimninu niicleotidc concentration with I1PLC. Thiopurinc methyltransferase activity [median (range, l() lll~9 0 th percentile)] was significantly (p < 0,05) higher in patients (n -39) receiving axathioprine [285 (218-362) vs, 262 (160-352) inU/l erythrocylcs] than in healthy blood donors as controls (n = 120). When stratified according to thiopurinc methyltransferase phenotypc, one patient homozygous for the low allele exhibited an excessive crylhrocyte 6-lhioguaninc nuclcotide concentration (2210 pmol/0.8 · I0 9 erylhrocytcs). Heterozygous patients had significantly higher 6-thioguaninc niicleotidc concentrations (median: 435 pmol/0.8 · 1 erythrocytes) compared with concentrations in patients homoxygous for the high allele (median: 86 pmol/0.8 · 10
Introduction
In immunosuppressive cyclosporin-based triple therapy transferase. Xanthine oxidase is not genetically polyaficr organ transplantation, axathioprine is often used us morphic and if not pharmacologically blocked this pathan antiproliforative agent. Azathioprine represents the S-way leads to 6-thiourie acid. In contrast, thiopurinc imidaxolc derivative of 6-mercaptopurine and is rapidly melhyltransferase displays a common genetic polymorcleaved to this drug in vivo by glutathione-S-transfcrasc phism (11 -13) . This polymorphism leads in 0.3% of (1) . It is generally agreed that 6-thioguaninc nueleotidos, Caucasians to a complete deficiency of the enzyme, and which are synthcsiscd from 6-mercaptopurine through in about 11% to a heterozygous form with an enzyme several enxymatic steps including hypoxanthine-gua-activity of 40-60%, compared with individuals with the nine-phosphoribosyl transferase (2) , are the major toxic two high allelcs (14) . An accumulation of 6-thioguaninc species of 6-thiopurine derivatives ( fig. 1) (3, 4) . The nucleotides is therefore likely to occur if one of these determination of 6-thioguanine nucleotides in crythro-eatabolising pathways is altered. Thiopurine methylcytes is therefore an accepted means of estimating toxic-transferase is generally determined in erythrocytes, ity and efficacy of 6-mercaptopurinc treatment in pa-which are readily accessible, and there is a close correlatients with acute leukaemia (5-7) and after solid organ tion between activities measured in erylhrocytes and in transplantation (8-10). 6-Thiopurines are catabolised by other cells and organs e. g. liver, kidney and leukocytes two enzymes, xanthine oxidase and thiopurine methyl- (15) (16) (17) . Brythrocyte thiopurine methyltransferase of randomly selected healthy Europeans typically shows a biphasic frequency distribution, consistent with a codominant inheritance (12, 13) . One single point mutation, which leads to a substantial reduction of catalytic activity has been described (18) and recently a predominant 2-point mutation, which is present in about 70% of thiopurine methyltransferase deficient subjects was discovered (19) . Further factors complicating therapeutic management of thiopurines are their widely variable bioavailability (20, 21) and an increase of thiopurine methyltransferase activity during therapy consistent with an induction phenomenon (10, 22) . These might be the main reasons for the fact, that until now, only one study has shown a close negative correlation between thiopurine methyltransferase and 6-thioguanine nucleotides (23) .
In patients receiving thiopurines for malignancies, i. e. where leukocyte suppression is desired, the dosage is mainly adjusted to achieve low white blood cell count. In contrast, in immunosuppressive triple therapy, azathioprine is most commonly used in a protocol-based standard dosage and only reduced if leukopenia occurs. On the other hand, transplant recipients, compared with acute lymphatic leukaemia and acute myeloic leukaemia patients under maintenance therapy, are at higher risk for complications of leukopenia since they receive a combination of immunosuppressive drugs. They may therefore particularly profit from therapeutic drug monitoring of the toxic 6-thioguanine nucleotides. Furthermore, in these patients it would be of benefit to investigate the correlation of 6-thioguanine nucleotides and drogenase; XO: Xanthine oxidase; TPMT: Thiopurine methyl transferase; SAH: S-Adenosyl homocysteine; SAM: S-Adenosyl methionine thiopurine methyltransferase in vivo, since if thiopurine methyltransferase phenotype is correlated with toxic metabolites, a stratification of each patient according to thiopurine methyltransferase activity prior to therapy may aid in planning subsequent immunosuppressive therapy, particularly with respect to the new immunosuppressants.
We studied erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations in 39 patients after heart and kidney transplantation under stable clinical conditions at least 3 months after the last blood transfusion, to elucidate the relationship between erythrocyte 6-thioguanine nucleotides and thiopurine methyltransferase activity.
Patients and Methods

Probands
Twenty-one heart transplant recipients and 18 kidney recipients with generally uncomplicated postoperative courses were included in this study. Thirty-eight patients had undergone transplantation at least 3 months prior to the investigation and none had blood transfusions within this time. The only exception was one thiopurine methyltransferase-deficient patient who was tested 2 months after transplantation. The immunosuppressive regimen consisted of cyclosporin A, the dosage being adjusted according to its concentrations in blood (200-350 g/l in heart recipients, 150-200 g/l in kidney recipients), steroids, which were tapered during the postoperative period, and azathioprine at a daily dosage median of 1 mg/kg body weight. Some patients received antilymphocyte antibodies as therapy induction for a maximum of 7 days immediately after transplantation. Patients with comedication with drugs which can potentially influence thiopurine metabolism, particularly xanthine oxidase inhibitors, and patients with» unstable kidney function (e. g. due to rejection episodes) were excluded. If patients were tested several times, the latest time point was considered for statistical evaluation unless creatinine concentrations were increased compared with earlier measurements in the same patient.
For comparison, blood samples of 120 healthy blood donors were also analysed for their erythrocyte thiopurine methyltransferase activity.
Methods
Erythrocyte preparation
Erythrocytes were obtained from NH 4 -heparinate anticoagulated whole blood by centrifugation at 2000 g for 10 min. Two washing steps were performed with Hank's balanced salt solution under the same conditions. Cells were finally rediluted to a haematocrit of about 0.40 and the exact haematocrit and red blood cell count for calculations of thiopurine methyltransferase activity and 6-thioguanine nucleotide concentration were determined with a Coulter STKS cell counting device. Samples were stored at -90 °C until analysis of thiopurine methyltransferase or 6-thioguanine nucleotides.
Tliiopurine methyltransferase assay
Erythrocyte lysates were analysed for their thiopurine methyltransferase activity by a modified method according to Weinshilboum et al. (24) . As proposed elsewhere, S-[me/Ay/-3 H]adenosylmethionine was used as methyl donor (12) and the chelating step was omitted since erythrocytes lack interfering enzymes requiring bivalent cations (15) . Lysates were incubated for l h at 37 °C with 6-mercaptopurine, S-[we///y/-3 H]adenosyl-methionine, dithiothreitol, and allopurinol. The formed [mef/iy/-3 H]6-mercaptopurine was liquid/liquid extracted with 120 mmol/1 isoamyl alcohol in toluene and the radioactivity was determined by -scintillation in a model LS3801 counter (Beckman Instruments, Munich, Germany). The radioactivity of the total reaction mixture was also determined. Results were corrected for"quench, chemical and radiochemical purity of S-adenosylmethionine and extraction efficacy (56-65%; determined in each run), and expressed as mU/1 packed erythrocytes). These modifications yielded an improvement of between day variation of the erythrocyte thiopurine methyltransferase assay from 9.5% to 5.9%. Within-series imprecision was 4.1-9.0% (100-350 mU/1 erythrocytes) in our laboratory with a dynamic range of this procedure of 17-920 mU/1 erythrocytes.
6-Thioguanine nucleotide assay
Erythrocyte lysates were hydrolysed in 1.5 mol/1 H 2 SO 4 at 98 °C for 1 hour, in order to convert the respective nucleotides to 6-thioguanine. A saturated solution of phenyl mercuric acetate in toluene/isoamyl alcohol at alkaline pH was used to extract compounds with sulfhydryl groups. After back-extraction into 100 mmol/1 HC1, samples were analysed by C18 reversed phase HPLC (Hypersil ODS 5 μπι 250 · 4.6 mm, MZ Analysentechnik, Mainz, Germany, guard column: RP select B 5 μπι, Merck, Darmstadt, Germany) under isocratic conditions (25). 6-Thioguanine spiked drug-free erythrocyte lysates were used for construction of a calibration curve with UV detection at 342 nm. 4-Mercapto-lH pyrazolo [3,4-d] pyrimidine was used as internal standard, and was detected at 322 nm (Shimadzu SPD 10 AV, Shimadzu Europe, Groburgwedel, Germany). If deviation from the assigned haematocrit (0.35) of sample preparation was > 0.05, a correction was performed with donor blood or Hank's balanced salt solution prior to the hydrolysis step. This is necessary since extraction efficacy decreases with the number of erythrocytes, with a resulting optimum at an haematocrit of about 0.35. Thioguanine concentrations were expressed as pmol/0.8 · 10 9 erythrocytes. Between-days imprecision was < 7% at concentrations of 100 pmol/0.8 · 10 9 erythrocytes and above, with a detection limit of 20 pmol/0.8 · 10 9 erythrocytes.
All reagents were of highest available purity. S-[we//?y/-3 H]adenosyl-methionine was purchased from Amersham (Braunschweig, Germany), isoamyl alcohol from J. T. Baker (Devender, The Netherlands) and toluene, borate, H 2 SO 4 , HC1 and NaOH from Merck (Darmstadt, Germany). All other chemicals were from Sigma Chem. (Deisenhofen, Germany).
Statistical analyses were performed with SAS statistical package, Ver.6.01 (SAS Inst. New York, USA). This study was approved by the local Ethics Committee.
Results
Erythrocyte thiopurine methyltransferase activity of 120 healthy donors showed a typical biphasic distribution ( fig. 2 ) with a cut-off for the putative heterozygous group at 167 mU/1 erythrocytes. The calculated cut-off point, based on the llth percentile of this donor group was 162 mU/l erythrocytes. The median for the whole group of healthy donors was significantly lower than in the group of patients under long-term therapy with azathioprine (262 vs. 285 mU/l erythrocytes; p < 0.05).
In the patient group, one subject showed a total thiopurine methyltransferase deficiency and five patients were identified with an intermediate phenotype ( fig. 3) . The upper limit of this intermediate group was 217 mU/l erythrocytes, defined as the 11th percentile of the patient group with the exclusion of the thiopurine methyltransferase deficient patient (since taking this case under consideration would over-represent this group, which has a frequency of 0.3% in a normal population).
Erythrocyte 6-thioguanine nucleotide concentrations displayed a broad distribution from 31 to 599 pmol/0.8 • 10
9 erythrocytes in patients with detectable erythrocyte thiopurine methyltransferase activity (fig. 4) . The highest 6-thioguanine nucleotide concentration observed was 2210 pmol/0.8 · 10 9 erythrocytes in the thiopurine methyltransferase-deficient patient. This was associated with an episode of leukppenia. Tab. 1 Erythrocyte 6-thioguanine nucleotide concentrations in heart and kidney recipients stratified according to erythrocyte thiopurine methyltransferase activity.
Thiopurine methyltransferase (mil/I erythrocytes) <17 17-210 >210 (n =1) (n = 5) (n = 33) When stratified according to thiopurine methyltransferase activity, significantly higher erythrocyte 6-thioguanine nucleotide concentrations were observed in the groups with low thiopurine methyltransferase activity (tab. 1).
Azathioprine dosage did not differ between these groups (median 75 mg/day; p = 0.88). Furthermore there was no correlation between azathioprine daily dose and erythrocyte-6-thioguanine nucleotide concentrations (r < 0.01; p = 0.431). A highly significant negative correlation was seen between thiopurine methyltransferase activity in erythrocytes and the respective concentrations of 6-thioguanine nucleotides ( fig. 5) , even when the patient with total thiopurine methyltransferase deficiency was excluded (r = -0.785; p < 0.01).
Discussion
The detoxification of azathioprine, used in immunosuppressive management after organ transplantation, is dependent on the common genetic polymorphism of thiopurine methyltransferase (11 -13, 14, 27) . This study showed that thiopurine methyltransferase activity is obviously influenced by thiopurines and shows an increase under therapy. This is in close agreement with results from studies in which thiopurine methyltransferase was measured in patients prior to and under treatment with azathioprine or 6-mercaptopurine, and thereafter (5, 22) .
Despite the well known metabolism of thiopurines, only one study has shown a close relationship between thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations (23) . This might be due to several uncertainties of azathioprine therapy, such as the induction phenomenon mentioned above, different dosages, especially if dosage is adjusted according to leukocyte count, and the variable bioavailability of this drug (20, 21) which is influenced by food intake (26) . In this study, we observed a close negative correlation of 6-thioguanine nucleotides and thiopurine methyltransferase in patients taking azathioprine. In these heart and kidney recipients, the observed highly significant correlation (r = -0.785) was probably due to the relatively constant dosage of 75 mg/day in this patient group.
High concentrations of erythrocyte 6-thioguanine nucleotides are associated with the risk of myelosuppression (5-7, 10), with related complications, such as septicaemia and consecutive multiple organ failure. As reported (27) , the patient with complete thiopurine methyltransferase deficiency and excessive 6-thioguanine nucleotide concentration subsequently died from this complication. Furthermore in a previous study, we showed that patients with 6-thioguanine nucleotide concentrations > 600 pmol/0.8 · 10 9 erythrocytes may develop leukopenia (10) . These findings suggest that one might expect an increased risk of toxic side effects in such patients under treatment with higher azathioprine dosage.
In therapeutic drug monitoring for azathioprine after solid organ transplantation the lower limit of erythrocyte 6-thioguanine nucleotides is hard to define, since the immunosuppressive regimen consists of a combination of drugs and there is a lack of simple quantities for assessing the immunosuppressive state of an individual patient. The data of this study demonstrate a close relationship between thiopurine methyltransferase activity and 6-thioguanine nucleotide concentration in transplant recipients under azathioprine therapy. It would therefore seem advisable to measure erythrocyte thiopurine methyltransferase prior to transplantation, to identify those patients with low or absent activity, who obviously carry an increased risk for toxic complications due to elevated 6-thioguanine nucleotides. In patients with lower or absent thiopurine methyltransferase, the concentrations of 6-thioguanine nucleotides should be monitored during azathioprine therapy to avoid toxic effects, and dosage could be adjusted at the start of therapy by taking erythrocyte thiopurine methyltransferase activity into account. Alternatively, determination of erythrocyte thiopurine methyltransferase prior to transplantation could be used to identify patients at high risk of azathioprine toxicity, who might more appropriately be treated with one of the new immunosuppressants such as tacrolimus or mycophenolate mofetil.
